GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $14.20.

Separately, D. Boral Capital reissued a “buy” rating and issued a $18.00 price objective on shares of GeoVax Labs in a research report on Thursday, February 27th.

Institutional Trading of GeoVax Labs

Several institutional investors have recently modified their holdings of the company. Virtu Financial LLC acquired a new position in shares of GeoVax Labs in the third quarter valued at $97,000. Citadel Advisors LLC acquired a new position in shares of GeoVax Labs in the 4th quarter valued at $104,000. Northern Trust Corp bought a new position in shares of GeoVax Labs during the 4th quarter worth about $29,000. Finally, Geode Capital Management LLC boosted its position in shares of GeoVax Labs by 59.0% during the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after acquiring an additional 33,440 shares in the last quarter. Institutional investors and hedge funds own 6.09% of the company’s stock.

GeoVax Labs Stock Performance

Shares of NASDAQ:GOVX opened at $1.35 on Friday. The business has a 50 day moving average price of $1.77 and a 200 day moving average price of $2.25. GeoVax Labs has a twelve month low of $1.09 and a twelve month high of $11.18.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.